GlaxoSmithKline PLC (GSK) yesterday beat expectations for its first-quarter revenue and profit, helped by sales of its blockbuster shingles vaccine Shingrix.
The London-listed drugmaker reported adjusted earnings per share of ￡0.37 on revenue of about ￡7 billion (US$8.74 billion).
Analysts were expecting earnings per share of ￡0.37 on revenue of about ￡6.5 billion, company-compiled consensus estimates showed.
Photo: EPA-EFE
The company’s blockbuster shingles vaccine generated ￡833 million, ahead of a GSK-compiled consensus of ￡829 million.
GSK reaffirmed its guidance for this year.
In February, the company predicted sales growth would this year increase 6 to 8 percent and adjusted operating profit would increase 10 to 12 percent at constant exchange rates.
On Wednesday, the company said it expected adjusted operating profit growth to be lower in the first half of the year, as cost increases are expected to affect drug launches, including its keenly watched respiratory syncytial virus (RSV) vaccine.
The company is a key player in the race that also includes Moderna Inc and Pfizer Inc to develop a safe and effective RSV vaccine, which, if approved, is expected to generate billions in sales.
Pfizer and GSK filed applications for US regulatory approval late last year. An decision on GSK’s application is expected by early next month.
Separately, Roche Holding AG’s first-quarter sales exceeded expectations, as revenue from new drugs helped offset a drop in the market for COVID-19 tests.
Sales fell 6.8 percent to 15.3 billion Swiss francs (US$17.2 billion), the Basel, Switzerland-based company said yesterday, beating analyst estimates.
Sales of eye drug Vabysmo and prescription flu treatment Xofluza exceeded expectations, as did revenue in Japan, thanks to orders of COVID-19 medicine Ronapreve. Cancer drug Tecentriq fell slightly short of expectations.
“In the last year we did have some setbacks,” Roche chief executive officer Thomas Schinecker said on a call with reporters.
Still, the company has more than 14 late-stage trials due to deliver results this year and aims to introduce three new medicines, he said.
“We don’t have to hide. We really see that we have a strong, productive R&D [research and development] organization,” he said.
Vabysmo would help drive growth in the coming years, with “still a lot of runway ahead” for sales, he said.
Additional reporting by Bloomberg
Semiconductor business between Taiwan and the US is a “win-win” model for both sides given the high level of complementarity, the government said yesterday responding to tariff threats from US President Donald Trump. Home to the world’s largest contract chipmaker, Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), Taiwan is a key link in the global technology supply chain for companies such as Apple Inc and Nvidia Corp. Trump said on Monday he plans to impose tariffs on imported chips, pharmaceuticals and steel in an effort to get the producers to make them in the US. “Taiwan and the US semiconductor and other technology industries
SMALL AND EFFICIENT: The Chinese AI app’s initial success has spurred worries in the US that its tech giants’ massive AI spending needs re-evaluation, a market strategist said Chinese artificial intelligence (AI) start-up DeepSeek’s (深度求索) eponymous AI assistant rocketed to the top of Apple Inc’s iPhone download charts, stirring doubts in Silicon Valley about the strength of the US’ technological dominance. The app’s underlying AI model is widely seen as competitive with OpenAI and Meta Platforms Inc’s latest. Its claim that it cost much less to train and develop triggered share moves across Asia’s supply chain. Chinese tech firms linked to DeepSeek, such as Iflytek Co (科大訊飛), surged yesterday, while chipmaking tool makers like Advantest Corp slumped on the potential threat to demand for Nvidia Corp’s AI accelerators. US stock
The US Federal Reserve is expected to announce a pause in rate cuts on Wednesday, as policymakers look to continue tackling inflation under close and vocal scrutiny from US President Donald Trump. The Fed cut its key lending rate by a full percentage point in the final four months of last year and indicated it would move more cautiously going forward amid an uptick in inflation away from its long-term target of 2 percent. “I think they will do nothing, and I think they should do nothing,” Federal Reserve Bank of St Louis former president Jim Bullard said. “I think the
Cryptocurrencies gave a lukewarm reception to US President Donald Trump’s first policy moves on digital assets, notching small gains after he commissioned a report on regulation and a crypto reserve. Bitcoin has been broadly steady since Trump took office on Monday and was trading at about US$105,000 yesterday as some of the euphoria around a hoped-for revolution in cryptocurrency regulation ebbed. Smaller cryptocurrency ether has likewise had a fairly steady week, although was up 5 percent in the Asia day to US$3,420. Bitcoin had been one of the most spectacular “Trump trades” in financial markets, gaining 50 percent to break above US$100,000 and
RSS